The study compared guaiac-based fecal occult blood test or fecal immunochemical test annually, fecal DNA every three years, flexibly sigmoidoscopy or computed tomographic colonography every five years and colonoscopy every 10 years. Researchers gathered outcome measures, including lifetime costs, number of cancers detected, incremental cost-utility ratios and more.
Researchers concluded fecal immunochemical test should be prioritized for colorectal screening in patients.
Read the study about the cost analysis of colorectal cancer screening modalities.
Read other coverage about colorectal screening:
– Researchers Investigate Possible Association of Inflammatory Markers and NSAIDs With CRC
– Researchers Revisit Surveillance Colonoscopy Utilization
– 4 Steps to Increase Screening Colonoscopy Cases
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.